
Project
All work
CG Oncology
Sector
Oncology
Oncolytic Immunotherapy
Stage
Late-stage & Commercial
Location
Texas, US
Year
2024
Services
Animation
Infographics & Illustration
VR & 3D
Pitch Decks
View website
Overview
Oncolytic immunotherapy for bladder cancer
CG Oncology develops oncolytic immunotherapies targeting hard-to-treat bladder cancer, enhancing combination treatments, and conducting clinical trials for regulatory approval. Reciprocal Space was engaged by CG Oncology to produce visual campaigns in order to support their fundraising, therapy commercialization, enhancing industry visibility and attracting investors and partners as well as improving patient education. In 2024 CG Oncology went public at a valuation of $1 bn.
The challenge
CG Oncology needed to explain an oncolytic immunotherapy for bladder cancer to investors, partners, physicians and patients as it moved towards commercialisation.
Our approach
We built one visual language for the mechanism of action and used it across infographics, animation, decks, the website and an immersive VR experience.
01
Animation
MoA animations for physicians and patients
We produced 3D mechanism-of-action animations, with versions tailored for healthcare professionals and for patients.
02
VR & 3D
An immersive MoA experience
To enhance CG Oncology’s scientific communication with physicians and collaborators, we developed a virtual reality mechanism-of-action experience. Visitors to the CG Oncology booth at the American Urology Association 2024 meeting could become fully immersed in the MoA, enhancing the company’s presence and impact at the conference.

03
Infographics & Illustration
Making a complex mechanism easy to follow
We visualised the complex mechanism of action of Cretostimogene Grenadenorepvec through clear and engaging infographics, used in CG Oncology’s corporate deck presentations and throughout their website.

Outcome
A consistent story from deck to conference floor
The same visuals now run across CG Oncology’s decks, website, animations and conference presence. In 2024 CG Oncology went public at a valuation of $1bn.
